

Consolidated Financial Results for the Nine Months Ended December 31, 2025 [Under Japanese GAAP]

February 4, 2026
Tokyo Stock Exchange

Company name: KYORIN Pharmaceutical Co., Ltd.

Code number: 4569

Web site: <https://www.kyorin-pharm.co.jp/>

Representative : Yutaka Ogihara, Representative Director, President and Chief Executive Officer

Contact: Sakurou Banba, Director, Finance & Accounting

TEL (03) 6374-9704

Scheduled date to commence dividend payments: -

Preparation of supplementary material on financial results: Yes

Holding of financial results briefing: None

(Amounts rounded down to the nearest million yen)

1. Consolidated financial results for the nine months ended December 31, 2025 (from April 1, 2025 to December 31, 2025)

(1) Consolidated operating results (cumulative)

(Percentage indicate year-on-year changes)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Nine months ended	Million yen	%	Million yen	%	Million yen	%	Million yen	%
December 31, 2025	92,456	3.6	4,609	47.9	5,097	35.8	4,119	68.9
December 31, 2024	89,286	2.3	3,115	−35.1	3,753	−30.4	2,439	−41.2

(Note) Comprehensive income: For the nine months ended December 31, 2025: 5,900 million yen (149.9%),

For the nine months ended December 31, 2024: 2,361 million yen (−41.8%)

	Basic earnings per share	Diluted earnings per share
Nine months ended	Yen	Yen
December 31, 2025	71.71	—
December 31, 2024	42.46	—

(2) Consolidated financial position

	Total assets	Net assets	Equity ratio
As of	Million yen	Million yen	%
December 31, 2025	194,266	138,869	71.5
March 31, 2025	193,618	136,285	70.4

(Ref.) Equity: For the nine months ended December 31, 2025: 138,869 million yen,

For the fiscal year ended March 31, 2025: 136,285 million yen

2. Dividends

	Annual dividends per share				
(Record date)	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2025	—	20.00	—	37.00	57.00
Fiscal year ending March 31, 2026	—	20.00	—		
Fiscal year ending March 31, 2026 (Forecast)			—	37.00	57.00

(Note) 1. Revisions to the dividend forecast in the current quarter: None

2. Breakdown of year-end dividend for the fiscal year ended March 31, 2025: Ordinary dividend 32.00 yen,
Special dividend; 5.00 yen

3. Forecast of consolidated for the year ending March 31, 2026 (from April 1, 2025 to March 31, 2026)

(Percentage indicate year-on-year changes)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Full year	127,000	—2.4	6,100	—51.5	6,300	—52.3	4,800	—47.2	83.55

(Note) Revisions to the forecast in the current quarter: None

4. Other

(1) Changes in significant subsidiaries during the period (Change in specified subsidiaries resulting in the scope of consolidation): None

Newly included: None, Excluded: None

(2) Adoption of accounting treatment specific to the preparation of quarterly financial statements : Yes

(3) Changes in accounting policies, changes in accounting estimates and restatements

(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None

(ii) Changes in accounting policies due to other than (i): None

(iii) Changes in accounting estimates: None

(iv) Restatements: None

(4) Number of shares issued (common stock)

(i) Number of issued shares at the end of the period (including treasury shares):

As of December 31, 2025 59,945,641 shares,

As of March 31, 2025 64,607,936 shares

(ii) Number of treasury shares at the end of the period:

As of December 31, 2025 2,499,262 shares,

As of March 31, 2025 7,159,087 shares

(iii) Average number of shares outstanding during the period:

Nine months ended December 31, 2025 57,448,393 shares,

Nine months ended December 31, 2024 57,448,842 shares

* This financial report is not subject to audit procedures by certified public accountants or audit firm.

* Explanations about the appropriate use of the business forecasts and other noteworthy points. These forecast performance figures are based on information currently available to the Company and may include uncertain factors or risk that affect our future performance. Accordingly, actual business results may materially differ from the forecasted figures due to various factors in the future.

(Methods for obtaining supplementary materials and content of financial results disclosure)

Supplementary Information will be made available on the Company's website in conjunction with the Summary of Consolidated Financial Results.